Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
05/09/2007 10:04
PR Newswire
FREISING-WEIHENSTEPHAN, Germany, September 5 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel
class of targeted human protein therapeutics, today announced successful
completion of a series of preclinical studies validating the use of
Anticalins(R) in ophthalmologic disease.
The studies reported by Pieris relate to PRS-055, an Anticalin(R)
specific for VEGF. VEGF is a key factor in the regulation of neovascular
permeability and is implicated in debilitating eye diseases such as
age-related macular degeneration (AMD), proliferative diabetic retinopathy
and retinopathy of prematurity. Intravitreal injection of PRS-055 has been
shown to inhibit VEGF-induced breakdown of the blood-retinal barrier in a
rabbit in vivo model. The antagonistic effect of PRS-055 has been shown to be
of equivalent potency to that of the approved ophthalmology product
Lucentis(R) (ranibizumab; Genentech / Novartis).
"These exciting results have demonstrated that Anticalins(R) are viable
candidates as potent biotherapeutics for diseases of the eye" said Dr Andreas
Hohlbaum, Director of Science and Preclinical Development of Pieris. "Based
on the success of the PRS-055 program to date, we are now selecting
technologies for depot and/or non-invasive drug delivery that will exploit
the favorable size and excellent stability characteristics of Anticalins(R)."
The preclinical data on PRS-055 will be presented on September 8th, 2007,
at the IV. International Symposium of the German Ophthalmological Society
(DOG) in Baden-Baden, Germany.
Further information is available at http://www.pieris-ag.com
Anticalin(R) is registered trademark of Pieris AG.
For further information, please contact:
Pieris AG
Phone +49-(0)-8161-1411-400
Dr Andreas Hohlbaum,
Director of Science and Preclinical Research
For further information, please contact: Pieris AG, Phone +49-(0)-8161-1411-400, Dr Andreas Hohlbaum, Director of Science and Preclinical Research